Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
primary hyperoxaluria, kidney transplantation, recurrence, lumasiran
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
27
07
2022
accepted:
08
12
2022
medline:
26
6
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Primary hyperoxaluria type 1 is a rare cause of kidney failure. Stiripentol, an inhibitor of lactate dehydrogenase A, and lumasiran, a small interfering RNA targeting glycolate oxidase, have been proposed as therapeutic options, but clinical data are scarce, especially in adults and transplanted patients. We describe the case of a 51-year-old patient with a biopsy-proven recurrence of oxalate nephropathy after a kidney-only transplantation. He received stiripentol and lumasiran without adverse events. Fourteen months after transplantation, graft function, serum, and urinary oxalate levels have remained stable, and kidney biopsy showed a complete regression of oxalate crystals. Further studies are needed to assess whether this strategy is effective and could replace liver-kidney transplantation.
Identifiants
pubmed: 36693470
pii: S0272-6386(23)00041-0
doi: 10.1053/j.ajkd.2022.12.005
pii:
doi:
Substances chimiques
stiripentol
R02XOT8V8I
lumasiran
RZT8C352O1
RNA, Small Interfering
0
Oxalates
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-116Informations de copyright
Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.